Abstract
Corneal scarring associated with various corneal conditions is a leading cause of blindness worldwide. The present study aimed to test the hypothesis that corneal stromal stem cells have a therapeutic effect and are able to restore the extracellular matrix organization and corneal transparency in vivo. We first developed a mouse model of corneal stromal scar induced by liquid nitrogen (N2) application. We then reversed stromal scarring by injecting mouse or human corneal stromal stem cells in injured cornea. To characterize the mouse model developed in this study and the therapeutic effect of corneal stromal stem cells, we used a combination of in vivo (slit lamp, optical coherence tomography, in vivo confocal microscopy, optical coherence tomography shear wave elastography, and optokinetic tracking response) and ex vivo (full field optical coherence microscopy, flow cytometry, transmission electron microscopy, and histology) techniques. The mouse model obtained features early inflammation, keratocyte apoptosis, keratocyte transformation into myofibroblasts, collagen type III synthesis, impaired stromal ultrastructure, corneal stromal haze formation, increased corneal rigidity, and impaired visual acuity. Injection of stromal stem cells in N2‐injured cornea resulted in improved corneal transparency associated with corneal stromal stem cell migration and growth in the recipient stroma, absence of inflammatory response, recipient corneal epithelial cell growth, decreased collagen type III stromal content, restored stromal ultrastructure, decreased stromal haze, decreased corneal rigidity, and improved vision. Our study demonstrates the ability of corneal stromal stem cells to promote regeneration of transparent stromal tissue after corneal scarring induced by liquid nitrogen.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
 
; Borderie, Marie 2 ; Grieve, Kate 3 ; Martos, Raphaël 4 ; Bocheux, Romain 5 ; Thu‐Mai Nguyen 6 ; Callard, Patrice 7 ; Chédotal, Alain 3 ; Borderie, Vincent M 1  
 
1 Institut de la Vision, Sorbonne Université, INSERM, CNRS, Paris, France; Centre Hospitalier National d'Ophtalmologie des 15‐20, DHU Sight Restore, INSERM‐DHOS CIC, Paris, France
2 Centre Hospitalier National d'Ophtalmologie des 15‐20, DHU Sight Restore, INSERM‐DHOS CIC, Paris, France
3 Institut de la Vision, Sorbonne Université, INSERM, CNRS, Paris, France
4 Laboratoire de Recherche Vasculaire Translationnelle, INSERM U1148, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
5 Laboratoire d'Optique et Biosciences (LOB) École polytechnique, CNRS UMR 7645, INSERM U 1182, Palaiseau cedex, France
6 Institut Langevin Ondes et images CNRS UMR 7587, INSERM U979 Physiques des ondes pour la médecine, ESPCI, Paris, France
7 Sorbonne Université, APHP, Hôpital Pitié Salpêtrière, Paris, France





